PTK2 and neoplasm: As a proof-of-concept to evaluate whether PET imaging using 64Cu-labeled OVA-CTLs could be used to predict the early-stage treatment efficacy and to select drugs for adjuvant cell-based therapies, we determined the tumor uptake changes in 64Cu-labeled OVA-CTLs after treatment with the FAK-inhibiting nanodrug (PLGA-FAKi).